Jane Parker, CEO of InterbrandHealth, comments on Excedrin's loyal brand following as its parent company, Novartis, continues to face issues of quality control.
More here.
 | | New regulations, advancing medical science and increasing
patient knowledge are creating an inhospitable environment
for traditional pharmaceutical marketing strategies.
It’s time to develop a new drug marketing model.
January 31, 2012
Download PDF |
The Boston Globe. Behind potent drug names, a complex mix of ingredients. Firms must navigate legal and linguistic hurdles for approval. July 4, 2011
Pharma Marketing Journal, a German publication, ran a piece by Michael Dumigan and Wes Wilkes on the changing role of brand in the health & life sciences industry. May 1, 2011
Medical Marketing & Media published a piece by Wes Wilkes, InterbrandHealth’s Executive Director of Global Strategy, on the changing role of brand in the health & life sciences industry. December 15, 2010
The Washington Business Journal quoted InterbrandHealth’s Executive Creative Director, R. John Fidelino, in an article entitled "Name blame: Ever wonder where drugs get those silly sobriquets?" August 6, 2010
Nycomed and Merck's DAXAS, a drug used in the treatment of chronic obstructive
pulmonary disease (COPD), receives approval from The European Commission.
July 6, 2010
Shire's VPRIV 
(velaglucerase alfa) receives FDA approval for the long-term treatment of Type 1
Gaucher Disease in pediatric and adult patients. February 26, 2010
Pfizer's Prevnar 13 
have been approved by the FDA/EMEA for the vaccination of children aged six weeks
through five years to protect against 13 varieties of the Streptococcus pneumoniae
bacteria. February 24, 2010
Gilead receives FDA approval for Cayston 
,
indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with
Pseudomonas aeruginosa. February 22, 2010
More than 30 industry experts, including InterbrandBHealth's Bunny Ellerin, tweet
their perspectives on the
top 10 healthcare social media predictions for 2010 in MedAdNews 
.
January 2010
InterbrandHealth's David Sun examines
global pharma branding trends for 2010 and beyond in Pharmaceutical Executive 
. November
2009
GSK's VOTRIENT (pazopanib) receives FDA approval for the treatment
of patients with advanced renal cell cancer. October 19, 2009
InterbrandHealth to Lead
CBI Webinar on Regulatory Success: John Breen will lead the webinar and
address the recent changes at the FDA and the pending initiation of a new Pilot
Program to evaluate brand names.
John will also be sharing vital insights on what market research will be
recommended for proposed brand name submissions to the FDA going forward. September
16, 2009
Novartis' Valturna 
,
a single pill combination of valsartan and aliskiren, receives FDA approval to treat
high blood pressure. September 16, 2009
InterbrandHealth Featured in HBA Eurovoice: Rebecca Robins featured on
"The Value of Branding" in the latest newsletter of the 
Europe.
September 2009
Novartis' Extavia 
(interferon beta-1b), the first in a new planned portfolio of multiple sclerosis
(MS) medicines, has been approved by the FDA. August 14, 2009
Schering-Plough's Saphris 
(asenapine) sublingual tablets receives FDA approval for the acute treatment of
bipolar I disorder and schizophrenia. August 13, 2009
InterbrandHealth's Rebecca Robins speaks on the value of brands at the HBA . July
29, 2009
InterbrandHealth's Rebecca Robins quoted in Fierce Biotech 
on the
strategic imperative of early commercialization. July 21, 2009
InterbrandHealth's Rebecca Robins quoted on the
changing landscape of pharmaceutical marketing in The Wall Street Journal 
.
July 20, 2009
GSK's Lamictal XR 
(lamotrigine) extended-release tablets receives FDA approval for a new epilepsy
indication. May 29, 2009
Otsuka's Samsca 
(tovalptan) receives FDA approval for hyponatremia. May 19, 2009
Vanda's Fanapt 
(iloperidone) receives approval by the FDA for the treatment of schizophrenia. May
6, 2009
InterbrandHealth's Bunny Ellerin speaks to the influence exerted by health blogs and social networks in Pharmaceutical Marketing. May 2009
Rebecca Robins comments in Italy's business publication 
, on the
pharmaceutical market in Italy. May 2009
Wyeth's CONBRIZA receives approval in Europe. Conbriza (bazedoxifene)
is a selective oestrogen receptor modulator (SERM) for the prevention and treatment
of postmenopausal osteoporosis. April 28, 2009
Intercell's Ixiaro 
is approved in Europe. Ixiaro is Europe's first vaccine to prevent Japanese Encephalitis.
March 30, 2009
Pfizer's FABLYN (lasofoxifene) receives approval in Europe for
the treatment of osteoporosis in post-menopausal women. March 24, 2009
InterbrandHealth's Rebecca Robins and John Breen will be speaking at the PTMG 
Spring Conference in Geneva on "The Battle for Brand Name Success: Navigating a Name to Global Regulatory Approval."March 23-24, 2009
InterbrandHealth's Rebecca Robins discusses brand integration in Medical Marketing & Media
Monthly Expert Forum. January 2009